As measurement of serum Tg is a well-established marker for residual or recurrent thyroid cancer [15], we suggest measurement of serum Tg and anti-Tg antibody levels to establish a post-operative baseline concentration and then serial estimates of Tg every 6 months for the first 2 years after initial treatment. Here, TG is linked to thyroid gland carcinoma.